Glutamine (Gln) prevents apoptosis in intestinal epithelial cells but the mechanism(s) remain unknown. Gln-derived metabolites include ammonia, glutamate (Glu), glutathione (GSH), and nucleotides. We previously showed that Gln potently inhibited apoptosis in cytokinetreated human colonic HT-29 cells; this effect was specific to Gln, unaffected by Glu and unrelated to intracellular glutathione. The current research examines mechanism(s) for Glninduced anti-apoptotic effects in HT-29 cells treated with tumor necrosis factor-alpha related apoptosis-inducing ligand (TRAIL). Proliferating cells were treated with Gln or selected Gln metabolites for 24 h. Cells were then treated with TRAIL and Gln or its downstream metabolites and apoptosis was assessed at 8 hr after treatment. The purine and pyrimidine precursors inosine and orotate inhibited TRAIL-induced apoptosis. However, inhibition of purine synthesis with azaserine did not alter the potent anti-apoptotic effect of Gln. In contrast, the pyrimidine synthesis inhibitor, acivicin, completely prevented this response. Supplementation with the pyrimidine uracil or the pyrimidine precursor orotate rescued the acivicin-induced blockade of Gln anti-apoptotic action. Removal of bicarbonate, a substrate for pyrimidine synthesis, also inhibited the anti-apoptotic effects of Gln. Uracil and thymine alone also significantly decreased TRAIL-induced apoptosis. The anti-apoptotic effects of Gln were independent of DNA/RNA synthesis as measured by flow cytometry and BrdU incorporation. In conclusion, Gln prevents TRAIL-induced apoptosis in HT-29 cells through a mechanism involving the pyrimidine pathway. Our data also demonstrate the novel anti-apoptotic effects of pyrimidine bases and their precursor, orotate in these human intestinal cells.
INTRODUCTION
Increased apoptosis occurs in inflamed/ulcerated areas of colonic mucosa in cases of inflammatory bowel disease (IBD) (2) and is associated with impaired mucosal healing (16) .
Cytokines that induce apoptosis in human intestinal cell lines, such as tumor necrosis factoralpha (TNF-) and interferon-gamma (IFN-), are believed to mediate the gut mucosal inflammation in IBD (35, 38). Thus, methods to reduce or prevent apoptosis in diseased and/or inflamed intestinal cells during increased cytokine expression may be potentially useful to enhance gut mucosal restitution in IBD and other conditions associated with intestinal inflammation.
Glutamine (Gln) is considered a conditionally essential nutrient during catabolic stress where it is a particularly important nutrient for gut epithelial and immune cells (for review, see (46) . Gln supplementation of the diet and/or parenteral nutrition improves nitrogen balance, immune function and indices of morbidity in animal models of disease and in critically ill patients (27, 46) . Gln has well-described trophic effects in gastrointestinal epithelia and both proliferative (4, 40) and anti-apoptotic effects (3, 6, 9, 28, 29, 43) have been observed. Gln induces proliferation and/or reduces apoptosis in the intestinal mucosa in vivo in weanling piglets (6) and in rat models of short bowel syndrome or bowel transplantation (12, 44) . Furthermore, Gln supplementation inhibits gut mucosal inflammation rats with experimentally-induced necrotizing enterocolitis and also maintains gut barrier function in models of intestinal atrophy or injury (5).
In vitro studies demonstrate that Gln inhibits apoptosis in gut epithelial cells. Use of Glnfree media induces spontaneous apoptosis in rat intestinal epithelial (RIE-1) cells, while addition of Gln to the culture media prevents spontaneous apoptosis (28, 29) . Gln also prevents oxidant and heat shock-induced cell death in rat small intestine-derived cells (IEC-6 and IEC-18) (3, 43).
We showed that Gln prevents cytokine-induced (TRAIL and tumor necrosis factor-/interferon-) apoptosis in the human intestinal epithelial cell line HT-29 (9).
Gln is a major respiratory fuel for enterocytes through its metabolism by the rate-limiting enzyme glutaminase into its intermediary metabolites, glutamate (Glu) and ammonia (NH 3 ) (for review, see (26)). Glu serves as an energy source through entry into the tricarboxylic acid (TCA) cycle or biosynthesis into metabolites, including other amino acids such as proline, arginine and citrulline (23). Glu is also an important precursor for synthesis of the endogenous thiol antioxidant GSH, which itself has anti-apoptotic properties under conditions of oxidative stress (17) . Finally, Gln is essential for the synthesis of purine and pyrimidine nucleotides. Our previous study showed that Gln's ability to prevent TRAIL-induced apoptosis in HT-29 cells was specific to Gln and could not be replicated with other amino acids including Glu (9). The results also showed that these anti-apoptotic effects required glutaminase and/or amidotransferase activity (both of which are inhibited with diazonorleucine) but were independent of intracellular GSH production which would depend on glutaminase activity. However, the amidotransferase activity, which appears to be necessary for Gln's anti-apoptotic effects, may be required for metabolic reactions include nucleotide synthesis.
Finally, our previous study found that a dose of 500 µM Gln completely inhibited TRAIL-induced apoptosis. This concentration is within the range of Gln concentrations found in normal, healthy human plasma (41) and likely considerably less than normal dietary consumption which averages < 10 g/d in healthy, non-vegans (21). However, Gln concentrations in both the blood and tissues decrease dramatically during critical illness or inflammation when its utilization exceeds its supply (22, 42, 45). Furthermore, many enteral diets and total parenteral nutrition solutions used in critically ill/inflamed patients lack sufficient amounts of Gln which further reduces Gln availability in the intestine. Thus, an inhibition of cytokine-induced intestinal cell apoptosis may provide an explanation for the beneficial effects of Gln supplementation in critically ill patients as inflammatory cytokines are often elevated in this patient population.
The purpose of this study was to determine potential mechanism(s) of Gln protection against cytokine-induced apoptosis and specifically whether this prevention involves nucleotide synthesis. For these studies, we used an HT-29 cell model in which we showed that Gln inhibited apoptosis induced with the cytokine, TRAIL (9). TRAIL is a member of the TNF superfamily and a known inducer of apoptosis in transformed intestinal epithelial cell lines including HT-29 cells (9, 11). Our data demonstrates that Gln prevents TRAIL-induced apoptosis in HT-29 cells through the pyrimidine pathway. Further, we show that the pyrimidine precursor, orotate, and the pyrimidine bases, uracil and thymine, have potent anti-apoptotic effects in this human gut cell line. containing 4 g/L glucose (Cellgro, Atlanta, GA) containing 10% fetal bovine serum (FBS), 2.0 mM Gln and 1% antibiotics (10000 U/L penicillin and 100 mg/ml streptomycin sulfate) at 37°C with 5% CO 2 /95%O 2 . Fresh media was added every two days, and cultures were passaged every 5-7 days to maintain sub-confluence. During experimentation, cells were seeded at a density of 8 x 10 5 cells/cm 2 in 6-well plates (Fisher Scientific, Pittsburgh, PA), unless otherwise indicated, and allowed to adhere using the above media for 24 h reaching ~ 60% confluence. During treatment, media was replaced with serum-free, Gln-free DMEM containing 1% antibiotics. For the bicarbonate starvation experiments, cells were pretreated with 24 h of serum-free DMEM followed by 8 h of treatment with either bicarbonate-containing DMEM or bicarbonate-free DMEM (Cellgro) supplemented with 11 mM HEPES adjusted to a pH = 7.2.
MATERIALS AND METHODS

Chemicals
Cell treatments. All experiments were conducted with HT-29 cells, treated, harvested, and assessed for percent apoptotic cells using flow cytometric analyses after 8 h of TRAIL (100 ng/ml) treatment according to methods outlined previously (9). As was shown previously, 500
µM Gln was the minimal concentration of Gln necessary to completely prevent TRAIL-induced apoptosis in HT-29 cells (9), thus, all Gln-supplemented cells were treated with 500 µM Gln in the present study. Non-TRAIL-treated cells in Gln-free culture medium served as controls. In our previous studies, 500 µM Gln specifically and completely inhibited the TRAIL-induced increase in the percentage of cells in the sub-G 1 peak, caspase-8 and -3 activation, and nuclear condensation (9) as well as cytochrome c release and caspase-9 activation (8).
To determine if Gln's anti-apoptotic effects were the result of Gln-derived ammonia production, cells were pretreated with 250 or 500 µM NH 4 Cl (a concentration half of or equivalent to the amount of NH 3 derived from 500 µM Gln metabolism by glutaminase, respectively) for 24 h and then treated with 100 ng/ml TRAIL, with or without 250 or 500 µM Statistical analyses. Differences between endpoints were compared across groups by one-way ANOVA. Specific treatment doses were compared post-hoc using the Fisher's least significant difference (PLSD) test (SPSS for Windows, SPSS Inc., Chicago, IL).
RESULTS
Ammonia treatment does not prevent apoptosis in TRAIL-treated HT-29 cells. Treatment with
TRAIL alone markedly increased apoptosis, while 500 µM Gln completely prevented this response (Fig. 2) . Addition of 250 µM or 500 µM NH 4 Cl alone without TRAIL had no effect on apoptosis. With TRAIL, apoptosis decreased marginally with 250 µM NH 4 Cl and there was no protection with 500 µmol/l NH 4 Cl.
Orotate and inosine treatment decrease TRAIL-induced apoptosis. Supplementation of cell culture medium with 1.25-5 mM the pyrimidine precursor, orotate, or the purine precursor, inosine, resulted in a dose-dependent decrease in TRAIL-induced apoptosis (Fig. 3) . Orotate decreased apoptosis to a far greater extent than did inosine. Combined inosine and orotate was less effective in preventing TRAIL-induced apoptosis suggesting an inhibitory effect of purines in the presence of orotate. Supplementation with either 5.0 mM uracil or thymine in the absence of Gln markedly decreased TRAIL-induced apoptosis (by 79 or 84 % respectively) (data not shown). Cytosine supplementation was substantially less effective than uracil or thymine, but did modestly decrease TRAIL-induced apoptosis compared to unsupplemented TRAIL-treated cells.
Inhibition of purine synthesis does not prevent Gln's anti-apoptotic effects. Increasing doses of
azaserine (25-500 µM) in the presence of Gln without TRAIL had no effect on apoptosis (Fig.   4 ). Azaserine treatment (25 µM) slightly increased apoptosis in the TRAIL + Gln-treated cells;
however, the ability of Gln to block TRAIL-induced apoptosis was unaffected by increasing doses of azaserine indicating that Gln does not block apoptosis through this pathway of nucleotide synthesis.
Inhibition of pyrimidine synthesis prevents Gln's anti-apoptotic effects. Concurrent treatment of HT-29 cells with 1-100 µM acivicin and Gln in the absence of TRAIL had no effect on apoptosis compared to controls (Fig.5A) . In contrast, addition of 1-100 µM acivicin to TRAIL + Gln treated cells resulted in a dose-dependent decrease of Gln's anti-apoptotic effects such that treatment with 100 µM acivicin completely prevented Gln's anti-apoptotic effects. Removal of bicarbonate (an essential component for pyrimidine synthesis) in the absence of TRAIL did not affect the percentage of apoptosis compared to bicarbonate-supplemented controls (Fig. 5B) .
TRAIL-treated cells starved of both Gln and bicarbonate exhibited a marked increase in apoptosis. However, bicarbonate-starved, Gln-supplemented cells exhibited a moderate decrease in apoptosis whereas Gln + bicarbonate supplementation completely prevented TRAIL-induced apoptosis. Taken together, these two experiments strongly suggest that pyrimidine synthesis is a mechanism for Gln's anti-apoptotic effects. (Fig. 6a ).
Gln and uracil additively inhibit apoptosis. Supplementation of TRAIL-treated cells with either 50 µM Gln or 500 µM uracil reduced TRAIL-induced apoptosis to a similar degree (56% and 61% respectively) (Fig. 6b) . However, concurrent supplementation with 50 µM Gln and 500 µM uracil significantly decreased TRAIL-induced apoptosis to a greater extent than either of these agents alone at these concentrations. These data indicate that Gln and uracil additively inhibit TRAIL-induced apoptosis in HT-29 cells.
Gln supplementation increases UDP-hexose concentrations. Evidence suggests that pyrimidines synthesized de novo are preferentially utilized to synthesize UDP-sugars and CDPphospholipids (37). In HT-29 cells, supplementation with 500 µM Gln for 1 hour increased UDP-glucose from 74 ± 29 pmol/mg protein to 144 ± 40 pmol/mg protein (a 96% increase; p = 0.007) and UDP-galactose was increase from 20 ± 9 pmol/mg protein to 31 ± 6 pmol/mg protein (a 55% increase; p= 0.005). These data indicate that Gln supplementation increases the production of UDP-hexoses, a known pyrimidine downstream product.
Gln prevents TRAIL-induced apoptosis by a mechanism independent of nucleic acid
(DNA/RNA) synthesis. TRAIL treatment resulted in a marked increase in the number of apoptotic cells (Fig. 7a, BrdU incorporation per number of cells with TRAIL was similar to controls whereas BrdU incorporation increased markedly with Gln + TRAIL supplementation (Fig. 7b) . Both acivicin and azaserine substantially inhibited Gln's induction of nucleic acid synthesis indicating that Gln's anti-apoptotic effects are not the result of increased DNA/RNA synthesis.
DISCUSSION
Our study demonstrates for the first time that the Gln-derived pyrimidine pathway is a mechanism for Gln's prevention of cytokine-induced apoptosis in human intestinal epithelial cells. Pyrimidines (including cytosine, thymine, and uracil) are synthesized de novo from Gln, ATP, and bicarbonate through the action of CAD-a single multidomain protein with multiple enzymatic activities (including Carbamoyl phosphate synthetase II (CPS II)-Aspartate transcarbamoylase-Dihydroorotase). Orotate, an intermediate of the pyrimidine pathway, is generated early in pyrimidine metabolism through CAD action and serves as a precursor for uracil, cytosine, and thymine [for review, see (14)].
Evidence for a pyrimidine pathway mechanism as explanation for Gln's anti-apoptotic effects in this study includes: 1) complete inhibition of glutamine's anti-apoptotic effects with acivicin (an inhibitor of CPS II); 2) prevention of Gln's effects with bicarbonate starvation (an essential precursor for pyrimidine synthesis); and 3) anti-apoptotic effects of treatment with the pyrimidine bases uracil and thymine and the pyrimidine precursor orotate in the absence of glutamine. Furthermore, this anti-apoptotic effect was isolated to the pyrimidines, uracil and thymine, was not the result of an increase in nucleic acid (DNA/RNA) synthesis, and was moderately inhibited with the addition of the purine precursor, inosine. Our data also show that glutamine prevention of apoptosis is not the result of N production (as ammonia) or the purine pathway. Thus, these results suggest a novel mechanistic pathway for the previously identified anti-apoptotic effects of Gln in HT-29 cells (9). In addition, this study shows for the first time that the pyrimidine precursor, orotate, and the pyrimidine bases (uracil and thymine) have antiapoptotic effects in cytokine-treated human gut epithelial cells.
Glutaminase activity is necessary for the release of the amido nitrogen from Gln for pyrimidine synthesis. In our previous studies, glutaminase inhibition with diazo-6-norleucine (DON) prevented Gln's anti-apoptotic effects (9), but supplementation with the glutaminase products glutamate (Glu) or NH 3 did not prevent TRAIL-induced apoptosis. DON also functions as an amidotransferase inhibitor, and thus can prevent the transfer of the amido N group of Gln in the first step of pyrimidine synthesis. Taken together, these findings support the importance of CAD action, Gln's amido N, and thus pyrimidine synthesis, as a mechanism for Gln's antiapoptotic effects in HT-29 cells. Purine synthesis likewise depends on Gln for its amido nitrogen source; however, in our in vitro cell model, the purine pathway did not appear to be involved in Gln's prevention of TRAIL-induced apoptosis.
The specific physiological mechanism(s) through which pyrimidines inhibits TRAIL- It is interesting to note that higher concentrations of the pyrimidine precursor orotate were necessary to achieve inhibition of apoptosis in our model of cytokine-induced apoptosis when compared to Gln. However, the concentration of uracil that substantially inhibited TRAILinduced apoptosis (1.0 mM) was much lower and closer to that of Gln. Both the concentrations of orotate and uracil used in this study are higher than what is present in the normal diet. For example, skim milk has been found to contain up to 0.783 mM orotate (25) while infant formulas may contain up to 0.66 mM orotate (7). Mixed nucleotide-containing formula diets contain a mixture of nucleotides in the µM range (31); however, humans studies have been conducted with orotate at concentrations up to 6 g/d (19). Thus, concentrations similar to that of our study might be possible with supplementation.
One explanation for the observed concentration differences in our model may be that nucleotide synthesis through the Gln-dependent de novo pathway is more efficient than nucleotide synthesis through the salvage pathway in HT-29 cells (for review, see (14)). Moreover, the effect of TRAIL ± Gln supplementation on Gln metabolism and bioavailability remains to be determined.
In conclusion, our data show that Gln prevents cytokine-induced apoptosis in effects. Cells were treated as follows: A) pretreated with 500 µM Gln and 0, 1, 10 or 100 µM acivicin for 24 h followed by the same treatments plus 100 ng/ml TRAIL for 8 h; or B) pretreated with serum-free media for 24 h followed by 8 hours of 100 ng/ml TRAIL with or without 500 µM Gln ± bicarbonate. C) pretreated with 500 µM Gln, 5mM orotate or 5 mM uracil with or without acivicin (100 µM) for 24 h followed by the same treatments plus 100 ng/ml TRAIL for 8 h. Controls were untreated and TRAIL-treated cells were treated with TRAIL alone. Bars not sharing the same letters are significantly different (p<0.05). Gln and azaserine or acivicin for 24 h. TRAIL was then added for 8 h and flow cytometry was performed. Cell treatments consisted of A) 100 ng/ml TRAIL, B) 500 µM Gln + 100 ng/ml TRAIL, C) 500 µM Gln + 500 µM azaserine, D) 500 µM Gln + 100 µM acivicin, E) 500 µM Gln + 100 µM azaserine + 100 ng/ml TRAIL, or F) 500 µM Gln + 100 µM acivicin + 100 ng/ml TRAIL. Cells were pretreated with 500 µM azaserine or 100 µM acivicin with or without 500 µM Gln for 24 h followed by the same treatments plus 100 ng/ml TRAIL for 8 h and BrdU and cell number were determined. Control cells were treated with serum-free media without Gln. Bars not sharing the same letters are significantly different (p<0.05). 
